BR112014002659A2 - molécula variante de receptor de ativador de plasminogênio de uroquinase (upar), seu uso, anticorpo, fragmentos de ligação a antígenos recombinantes ou sintéticos do mesmo e composição farmacêutica - Google Patents

molécula variante de receptor de ativador de plasminogênio de uroquinase (upar), seu uso, anticorpo, fragmentos de ligação a antígenos recombinantes ou sintéticos do mesmo e composição farmacêutica

Info

Publication number
BR112014002659A2
BR112014002659A2 BR112014002659A BR112014002659A BR112014002659A2 BR 112014002659 A2 BR112014002659 A2 BR 112014002659A2 BR 112014002659 A BR112014002659 A BR 112014002659A BR 112014002659 A BR112014002659 A BR 112014002659A BR 112014002659 A2 BR112014002659 A2 BR 112014002659A2
Authority
BR
Brazil
Prior art keywords
upar
recombinant
plasminogen activator
urokinase plasminogen
activator receptor
Prior art date
Application number
BR112014002659A
Other languages
English (en)
Inventor
Sidenius Nicolai
Gandhi Sonu
Original Assignee
Ifom Fond St Firc Di Oncologia Molecolare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifom Fond St Firc Di Oncologia Molecolare filed Critical Ifom Fond St Firc Di Oncologia Molecolare
Publication of BR112014002659A2 publication Critical patent/BR112014002659A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo molécula variante de receptor de ativador de plasminogênio de uroquinase (upar), seu uso, anticorpo, fragmentos de ligação a antígenos recombinantes ou sintéticos do mesmo e composição farmacêutica a invenção refere-se a variantes do receptor de ativador de plasminogênio de uroquinase (upar) que exibem atividade de ligação a vitronectina (vn) notavelmente maior, possivelmente causada por uma exposição mais eficiente do sítio de ligação a vn. a presente invenção também se refere a anticorpos criados contra as ditas variantes de upar, capazes de se ligar ao sítio de ligação a vn de upar e em seguida, atuar como inibidores de funções de upar, atuando como antagonistas funcionais de funções de upar ativadas por vn. na presente invenção, tais anticorpos são derivados monoclonais, policlonais, sintéticos ou recombinantes do mesmo, como anticorpos sintéticos (scfv) de bibliotecas de exibição de fagos. os anticorpos da invenção atuam como antagonistas competitivos.
BR112014002659A 2011-08-05 2012-08-02 molécula variante de receptor de ativador de plasminogênio de uroquinase (upar), seu uso, anticorpo, fragmentos de ligação a antígenos recombinantes ou sintéticos do mesmo e composição farmacêutica BR112014002659A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515506P 2011-08-05 2011-08-05
PCT/EP2012/065198 WO2013020898A1 (en) 2011-08-05 2012-08-02 Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies

Publications (1)

Publication Number Publication Date
BR112014002659A2 true BR112014002659A2 (pt) 2019-09-24

Family

ID=46598575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002659A BR112014002659A2 (pt) 2011-08-05 2012-08-02 molécula variante de receptor de ativador de plasminogênio de uroquinase (upar), seu uso, anticorpo, fragmentos de ligação a antígenos recombinantes ou sintéticos do mesmo e composição farmacêutica

Country Status (9)

Country Link
US (1) US20140161803A1 (pt)
EP (1) EP2739305A1 (pt)
JP (1) JP2014529581A (pt)
CN (1) CN103930128A (pt)
AU (1) AU2012293720A1 (pt)
BR (1) BR112014002659A2 (pt)
CA (1) CA2842281A1 (pt)
IL (1) IL230427A0 (pt)
WO (1) WO2013020898A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
WO2019165105A1 (en) * 2018-02-26 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Ligands of the urokinase receptor and their use in treating, detecting, and imaging cancer
AU2020271012A1 (en) * 2019-04-08 2021-09-09 Phanes Therapeutics, Inc. Humanized anti-DLL3 chimeric antigen receptors and uses thereof
WO2022261403A1 (en) * 2021-06-11 2022-12-15 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting upar and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035969A2 (en) 1996-03-28 1997-10-02 Chiron Corporation Peptide ligands of the urokinase receptor
WO2001017544A1 (en) 1999-09-03 2001-03-15 The Brigham And Women's Hospital, Inc. Peptides that bind to urokinase receptor
CA2568428C (en) 2004-05-25 2020-12-29 Attenuon, Llc Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy
US7951589B2 (en) 2005-03-11 2011-05-31 Wilex Ag Monoclonal antibodies specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
DK2117571T3 (en) 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
CN101050237A (zh) 2007-02-26 2007-10-10 刘建宁 一种阻断uPA与uPAR相互作用的化合物及其应用
WO2012085076A1 (en) * 2010-12-22 2012-06-28 Ifom Fondazione Istituto Firc Di Oncologia Molecolare uPAR-ANTAGONISTS AND USES THEREOF

Also Published As

Publication number Publication date
CA2842281A1 (en) 2013-02-14
JP2014529581A (ja) 2014-11-13
US20140161803A1 (en) 2014-06-12
AU2012293720A1 (en) 2014-02-27
WO2013020898A1 (en) 2013-02-14
CN103930128A (zh) 2014-07-16
EP2739305A1 (en) 2014-06-11
IL230427A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
CY1119852T1 (el) Σκευασμα αντισωματος και θεραπευτικα σχηματα
ECSP13012792A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
BR112014002659A2 (pt) molécula variante de receptor de ativador de plasminogênio de uroquinase (upar), seu uso, anticorpo, fragmentos de ligação a antígenos recombinantes ou sintéticos do mesmo e composição farmacêutica
BR112013017080A8 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
MX370199B (es) Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
MA34091B1 (fr) Anticorps anti-cd40
MX341921B (es) Proteinas de union a antigeno.
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
PE20120591A1 (es) Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
AR069775A1 (es) Anticuerpos bivalentes biespecificos
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
EA201000018A1 (ru) Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения
EP2534179A4 (en) UPAR BINDING AGENT AND METHOD FOR THEIR USE
EA201201273A1 (ru) Моноклональные антитела к с-мет
CY1121980T1 (el) Αντισωματα anti-cd26 και χρησεις εξ αυτων
AR084627A1 (es) Formulacion farmaceutica que comprende una droga biofarmaceutica
EA200970113A1 (ru) Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н
BR112019010903A2 (pt) estrutura de cristal de gremlin-1 e anticorpo inibidor
AU2011347327A8 (en) uPAR-antagonists and uses thereof
EA201391618A1 (ru) Комбинация, содержащая умеклидиний и кортикостероид
CO7270463A2 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición
EA201391729A1 (ru) Состав, содержащий антитело

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.